Encompass Health (EHC) Q1 2026 earnings review
Strong Profitability Masks Decelerating Organic Volume
Encompass Health posted a solid Q1 with a 9.0% revenue increase and an 11.2% jump in Adjusted EBITDA, prompting management to raise full-year guidance. However, beneath the impressive headline margins, the organic growth engine is sharply decelerating. Same-store discharge growth collapsed to 1.6%—the lowest in over two years—indicating that top-line gains are increasingly dependent on pricing (+3.7% revenue per discharge), Medicaid supplemental payments, and new facility additions. While exceptional labor cost control expanded margins, a 12.9% drop in Adjusted Free Cash Flow and looming regulatory headwinds from the TEAM model and RCD expansion introduce notable risks.
🐂 Bull Case
Adjusted EBITDA grew 11.2%, outpacing revenue. Salaries and benefits dropped to 51.6% of revenue from 52.4% a year ago, reflecting sustained structural improvements in contract labor utilization and premium pay.
Net patient revenue per discharge grew 3.7% YoY to $22,633, supported by a favorable ~3.0% Medicare pricing update and 2.0-3.0% bumps in managed care contracting.
🐻 Bear Case
Same-store discharge growth decelerated sharply to 1.6% from 4.4% a year ago. Without the benefit of newly opened hospitals, organic patient demand appears to be stalling.
Adjusted Free Cash Flow fell 12.9% YoY to $193.8 million, driven by negative working capital swings and a substantial increase in cash tax payments ($23.3M vs normalized levels in prior Q1s).
⚖️ Verdict: ⚪
Neutral. The guidance raise and stellar cost controls are commendable, but paying for growth via acquisitions and de novos while organic volume (same-store discharges) drops below 2% is a concerning break in trend. The valuation margin of safety is thinning.
Key Themes
Organic Volume Plummets
Same-store discharge growth—the truest indicator of underlying demand and market share—fell to 1.6% in 26Q1. This marks a stark deceleration from the consistent 4%+ growth seen throughout early 2025. The company relied on new-store additions (2.7% growth contribution) to salvage the quarter's 4.3% total discharge growth. If same-store volume does not recover, the aggressive de novo pipeline becomes risky.
Exceptional Labor Cost Leverage
Management continues to execute brilliantly on labor. Salaries and benefits dropped 80 basis points YoY as a percentage of revenue (to 51.6%). This efficiency drove Adjusted EBITDA margins to 22.0% (up from 21.5% in 25Q1), proving that the reduction in premium contract labor achieved in 2025 is structural rather than temporary.
Aggressive Capacity Expansion Pushing Top-Line
With organic growth slowing, physical expansion is carrying the weight. Encompass opened a 49-bed hospital in Irmo, SC, and added 44 beds to existing facilities this quarter. The FY26 pipeline remains aggressive, targeting 8 new hospitals (389 beds) and ~175 bed additions. This capital deployment guarantees a steady base of inorganic revenue growth.
Regulatory Friction Expanding (RCD & TEAM)
The Review Choice Demonstration (RCD) rollout hit Texas (24 hospitals) in March 2026 and heads to California (3 hospitals) in May 2026. While management previously downplayed the Alabama pilot as 'ordinary course of business,' extending this pre-claim review to 27 more hospitals adds significant administrative burden. Additionally, the new CMS TEAM bundled payment model now encompasses 89 EHC facilities, creating potential disruption in acute-care referral patterns.
Medicaid Supplemental Payments Prop Up Revenue
'Other' revenue surged 40.3% YoY to $52.9M. This was heavily driven by a $15.3M increase in Medicaid supplemental payments (with $4.9M relating to prior periods). Conversely, provider tax expenses simultaneously rose $9.7M. While net positive, investors should strip out these volatile supplemental payments when evaluating core pricing power.
Other KPIs
Reversing. Dropped 12.9% YoY from $222.4M in 25Q1. The decline was heavily impacted by negative working capital swings (-$28.6M impact) and an increase in cash tax payments (-$22.8M impact). This highlights a growing disconnect between Adjusted EBITDA generation and actual cash conversion.
Stable. The balance sheet remains pristine. Encompass successfully amended its credit agreement to extend the maturity to 2031, providing vast liquidity to fund its heavy CapEx pipeline ($695M-$755M targeted for 2026) and continued share buybacks ($71.6M executed in Q1).
Stable but creeping up. Up 20 basis points YoY from 2.0%. Given the rollout of RCD in major states like Texas, an uptick in bad debt from denied claims is a crucial metric to monitor.
Guidance
Stable. The midpoint ($6.42B) implies 8.2% YoY growth compared to FY25. This was raised slightly from previous guidance but implies a slight deceleration from Q1's 9.0% pace, likely factoring in the normalization of Medicaid supplemental payments and slowing organic volume.
Decelerating. The midpoint ($1,365M) implies 7.7% YoY growth vs FY25. Since Q1 delivered 11.2% growth, management expects margin pressure in the remaining three quarters, citing $18-$22M in pre-opening and ramp-up costs for future hospitals.
Decelerating. Raised from the previous $5.81-$6.10 range. Using the midpoint of $6.00, this implies roughly 10% growth over FY25's $5.45, a notable step down from the robust 16.8% YoY growth captured in 26Q1.
Key Questions
Same-Store Volume Drop
Same-store discharges decelerated aggressively to 1.6%. How much of this is driven by broader acute-care hospital admission trends versus internal capacity constraints or changing Medicare Advantage referral behaviors?
Texas RCD Implementation
With the Review Choice Demonstration rolling out to 24 hospitals in Texas last month, are you seeing any early signs of delayed admissions, increased denial rates, or a spike in administrative staffing costs?
TEAM Model Referral Impacts
Now that the CMS TEAM bundled payment model is live and affecting 89 of your hospitals, have you witnessed any acute-care partners actively altering their post-acute network preferences to avoid IRFs for covered procedures?
Cash Flow Conversion
Adjusted Free Cash Flow fell nearly 13% despite EBITDA growing 11%. Can you detail the structural changes in cash tax payments or working capital cycles that caused this divergence, and will they persist through FY26?